FDA ap­proves Cidara's Rez­za­yo as an­ti­fun­gal treat­ment for can­didemia and in­va­sive can­didi­a­sis

Cidara Ther­a­peu­tics’ an­ti­fun­gal Rez­za­yo (reza­fun­gin) has been ap­proved by the FDA un­der pri­or­i­ty re­view for the treat­ment of can­didemia and in­va­sive can­didi­a­sis in adults with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER